Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Ovid Therapeutics ( (OVID) ).
On April 17, 2026, Ovid Therapeutics Inc. saw the expiration of its Series A Warrants that had been issued in an October 2025 private placement. The warrants covered 38,481,325 common shares, of which investors chose to exercise rights into 33,597,860 shares of common stock at $1.40 per share and 4,883,464 pre-funded warrants at $1.399 per share, generating approximately $53.9 million in gross proceeds for the company.
The completion of these warrant exercises strengthens Ovid Therapeutics’ capital position, potentially providing additional resources to fund its development programs and corporate initiatives. This inflow of capital may improve the company’s financial flexibility and could influence its strategic options, including advancing pipeline assets or supporting ongoing operations for stakeholders and investors.
The most recent analyst rating on (OVID) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page.
Spark’s Take on OVID Stock
According to Spark, TipRanks’ AI Analyst, OVID is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and negative free cash flow), partially offset by a strong low-debt balance sheet and improved 2025 trends. Technicals are favorable with price above key moving averages and positive MACD, and a positive financing/clinical update supports the development runway, while valuation remains constrained by lack of profitability and no dividend support.
To see Spark’s full report on OVID stock, click here.
More about Ovid Therapeutics
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies, primarily in the neuroscience space, targeting patients with rare neurological conditions and related disorders. The company operates in the life sciences industry, seeking to advance innovative treatments that address significant unmet medical needs in specialized markets.
Average Trading Volume: 3,055,713
Technical Sentiment Signal: Buy
Current Market Cap: $364M
For an in-depth examination of OVID stock, go to TipRanks’ Overview page.